This study aims at the identification and functional characterization of glucagon-like peptide 1 (7-36) amide (GLP-1) receptor in islets from Golden Syrian hamsters. Using a polyclonal antibody against rat GLP-1 receptors, Western blotting of the islet proteins revealed two major bands of 44 and 70 kDa, similar to those found in rat islets, RINm5F cells, and HIT-T15 cells. In Northern blots, transcripts of 2.7, 3.6 and 3.7 kb were observed in rat islets and RINm5F cells after hybridization with rat GLP-1 receptor cDNA probes of either 21 9 bp or 1.5 kb. Such was not the case in either hamster islets or HIT-T15 cells. However, a single 3.6-kb transcript was observed in the latter two cases when a human GLP-1 receptor cDNA probe of 1.6 kb was used for hybridization. In the isolated perfused pancreas of Golden Syrian hamsters, a rise in D-glucose concentration from 3.3 to 8.3 mM caused a biphasic stimulation of insulin release, which was further increased by either GLP-1 or glucagon (10(-9)M each). The enhancing action of GLP-1 on glucose-stimulated insulin secretion was much more marked than that of glucagon. The rise in D-glucose concentration decreased by 46+/-4% the release of glucagon, but GLP-1 failed to exert any obvious effect on glucagon secretion in the presence of 8.3 mM D-glucose. These results indicate that GLP-1 receptors are expressed in islets of Golden Syrian hamsters with an extracellular part possessing the same immunoreactivity as the rat islet GLP-1 receptors. The expression of the mRNA for the GLP-1 receptor differs, however, from that found in rat or human islets.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1385/ENDO:8:3:323 | DOI Listing |
Am J Kidney Dis
January 2025
Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Hospital Study Group of ARF (NSARF), Taipei, Taiwan.
Rationale & Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiac and kidney outcomes in patients with diabetes; however their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR) is uncertain. This study evaluated the effects of GLP-1RAs on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD).
Study Design: Systematic review and meta-analysis of randomized controlled trials (RCTs) reported through May 25, 2024.
J Am Acad Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33133, USA.
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs influence the risk for age-related ocular diseases.
Design: Retrospective cohort study.
Am J Health Syst Pharm
January 2025
Veterans Health Care System of the Ozarks, Fayetteville, AR, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
January 2025
Birmingham School of Anaesthesia, West Midlands, UK.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as an important class of drugs in the management of Type 2 Diabetes Mellitus (T2DM) and obesity. There are rising concerns of pulmonary aspiration with these medications due to drug-induced gastroparesis. While definitive association is uncertain, it is essential to be prudent and manage these patients as per the current evidence and recommendations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!